Cabozantinib Oral Tablet

DRUG2 trials

Sponsors

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Girish Dhall, MD

Conditions

Hepatocellular Carcinoma (HCC)Neurofibromatosis 1Plexiform NeurofibromaSecond Line Treatment

Phase 1

Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas

RecruitingNCT06502171

Girish Dhall, MDNeurofibromatosis 1, Plexiform Neurofibroma

Start: 2026-06-09End: 2034-08-01Target: 30Updated: 2026-08-24

Phase 2

Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function

CompletedNCT04522908

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestHepatocellular Carcinoma (HCC), Second Line Treatment

Start: 2020-10-12End: 2024-10-04Updated: 2025-01-30

Related Papers

CaboRISE: A phase II study evaluating reduced starting dose and dose escalation of cabozantinib as second-line therapy for advanced HCC in patients with compensated liver cirrhosis.

Journal of Clinical Oncology2021-05-20